Fragment N2, a caspase-3-generated RasGAP fragment, inhibits breast cancer metastatic progression

The RasGAP N-terminal fragment generated by caspase cleavage protects cells in a Ras/PI3K/Akt-dependent manner that does not rely on NFkB activation. Running title: Anti-apoptotic mechanisms of the RasGAP N-terminal fragment

RasGAP, a regulator of Ras GTPase family members, is cleaved at low levels of caspase activity into an N-terminal fragment (fragment N) that generates potent antiapoptotic signals. At higher levels of caspase activity, fragment N is further cleaved into two fragments that strongly potentiate apoptosis. RasGAP could thus function as a sensor of caspase activity to determine whether a cell should...

Fragment 3 Asserted Fragment 2 Asserted Fragment 1 Asserted Assertion F 3 F 1 F 2 Invariant Tuple Space Fragment 3 Fragment 2 Fragment 1 Fragmentation Mapping

A RasGAP SH3 Peptide Aptamer Inhibits RasGAP-Aurora Interaction and Induces Caspase-Independent Tumor Cell Death

The Ras GTPase-activating protein RasGAP catalyzes the conversion of active GTP-bound Ras into inactive GDP-bound Ras. However, RasGAP also acts as a positive effector of Ras and exerts an anti-apoptotic activity that is independent of its GAP function and that involves its SH3 (Src homology) domain. We used a combinatorial peptide aptamer approach to select a collection of RasGAP SH3 specific ...

Caspase 3 in breast cancer.

PURPOSE An inability to undergo apoptosis is widely thought to contribute to both tumorigenesis and tumor progression. One of the key mediators of apoptosis is the thiol protease caspase 3. In this investigation, caspase 3 mRNA and protein expression in breast cancer was examined. EXPERIMENTAL DESIGN Caspase 3 was measured at the mRNA level using reverse transcription-PCR and at the protein l...

An unusual metastatic breast cancer presentation Report of a case

 ABSTRACTWe are reporting a 43-year-old female breast cancer case with a solitary metastatic adenocarcinoma in clivus. This patient with a stage II (T1N1M0) breast cancer history has been followed for 7 years.  Modified Radical Mastectomy (MRM) and 6 courses chemotherapy with CMF (Cyclophosphamide, Metotrexate, 5FU) regimen were done for her at the time of diagnosis. Also, she took tamoxifen tw...